Results for tag: "Human Recombinant Insulin"

The human recombinant insulin market is a segment within the endocrine and metabolic disorders drugs sector, focusing on the production and distribution of laboratory-synthesized insulin, which mimics the insulin produced by the human pancreas. This market caters to the management of diabetes mellitus, a condition characterized by high blood sugar levels resulting from defects in insulin secretion, insulin action, or both. Human recombinant insulin has revolutionized diabetes treatment since its introduction, providing a safer and more consistent alternative to animal-derived insulin products. Different forms of recombinant insulin, including rapid-acting, long-acting, and premixed analogs, have been developed to match the natural patterns of insulin secretion and allow personalized diabetes management. The market is driven by an increasing incidence of diabetes, advancements in recombinant DNA technology, and the quest for optimal glycemic control to prevent complications associated with diabetes. Prominent companies in the human recombinant insulin market include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, and Wockhardt. These companies engage in research and development, manufacturing, and commercialization of various insulin formulations and delivery devices to improve the lives of those affected by diabetes. Show Less Read more